QCG
EW icon

Quadrant Capital Group’s Edwards Lifesciences EW Stock Holding History

Quadrant Capital Group’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.78M Buy
22,266
+7,153
+47% +$590K 0.05% 313
2025
Q4 		$1.29M Buy
15,113
+136
+0.9% +$11.2K 0.04% 432
2025
Q3 		$1.16M Buy
14,977
+22
+0.1% +$1.72K 0.04% 434
2025
Q2 		$1.17M Buy
14,955
+4,290
+40% +$320K 0.04% 407
2025
Q1 		$773K Buy
10,665
+5,485
+106% +$393K 0.03% 493
2024
Q4 		$383K Buy
5,180
+156
+3% +$10.9K 0.03% 416
2024
Q3 		$332K Sell
5,024
-750
-13% -$54.5K 0.02% 470
2024
Q2 		$533K Buy
5,774
+439
+8% +$38.9K 0.04% 306
2024
Q1 		$510K Buy
5,335
+262
+5% +$22K 0.04% 309
2023
Q4 		$387K Sell
5,073
-660
-12% -$45.9K 0.03% 363
2023
Q3 		$397K Sell
5,733
-1,582
-22% -$127K 0.04% 321
2023
Q2 		$690K Sell
7,315
-15
-0.2% -$1.3K 0.07% 199
2023
Q1 		$606K Buy
7,330
+1,726
+31% +$136K 0.06% 224
2022
Q4 		$418K Sell
5,604
-595
-10% -$45.9K 0.05% 288
2022
Q3 		$512K Buy
6,199
+370
+6% +$35.6K 0.07% 205
2022
Q2 		$554K Buy
5,829
+204
+4% +$21.1K 0.07% 194
2022
Q1 		$662K Buy
5,625
+281
+5% +$31.5K 0.08% 181
2021
Q4 		$692K Buy
5,344
+73
+1% +$8.52K 0.08% 168
2021
Q3 		$597K Buy
5,271
+197
+4% +$22.5K 0.08% 168
2021
Q2 		$526K Buy
5,074
+281
+6% +$26.5K 0.08% 180
2021
Q1 		$401K Buy
4,793
+351
+8% +$29.7K 0.07% 205
2020
Q4 		$405K Sell
4,442
-144
-3% -$11.9K 0.08% 181
2020
Q3 		$366K Buy
4,586
+658
+17% +$51.3K 0.08% 160
2020
Q2 		$271K Sell
3,928
-3,815
-49% -$271K 0.06% 203
2020
Q1 		$489K Buy
7,743
+2,580
+50% +$186K 0.08% 210
2019
Q4 		$382K Buy
5,163
+621
+14% +$48.5K 0.05% 415
2019
Q3 		$318K Buy
4,542
+690
+18% +$48.5K 0.05% 411
2019
Q2 		$225K Sell
3,852
-1,086
-22% -$65.7K 0.04% 510
2019
Q1 		$301K Buy
4,938
+1,167
+31% +$66.6K 0.05% 351
2018
Q4 		$182K Buy
3,771
+363
+11% +$18.4K 0.05% 389
2018
Q3 		$188K Hold
3,408
– – 0.05% 257
2018
Q2 		$159K Hold
3,408
– – 0.06% 289
2018
Q1 		$150K Buy
3,408
+30
+0.9% +$1.3K 0.05% 303
2017
Q4 		$119K Buy
3,378
+72
+2% +$2.64K 0.05% 340
2017
Q3 		$115K Buy
3,306
+42
+1% +$1.6K 0.05% 344
2017
Q2 		$107K Sell
3,264
-363
-10% -$13.3K 0.05% 325
2017
Q1 		$109K Buy
3,627
+123
+4% +$3.85K 0.05% 329
2016
Q4 		$106K Sell
3,504
-105
-3% -$3.4K 0.05% 249
2016
Q3 		$138K Buy
3,609
+285
+9% +$10.7K 0.09% 185
2016
Q2 		$106K Buy
3,324
+75
+2% +$2.57K 0.07% 218
2016
Q1 		$92K Hold
3,249
– – 0.06% 238
2015
Q4 		$81K Buy
3,249
+111
+4% +$2.88K 0.06% 273
2015
Q3 		$72K Sell
3,138
-126
-4% -$3.04K 0.05% 304
2015
Q2 		$76K Buy
+3,264
New +$73.7K 0.05% 322

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Quadrant Capital Group's EW Position: Q1 2026 in Review

Quadrant Capital Group increased its Edwards Lifesciences (EW) stake by 47% in Q1 2026, buying an estimated $590K and bringing the position to 22,266 shares worth $1.78M. The position accounts for 0.05% of the portfolio, ranked #313.

Quadrant Capital Group first reported a position in EW in Q2 2015 and has held it in 44 quarters since. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Quadrant Capital Group held 22,266 shares of Edwards Lifesciences worth $1.78M as of Q1 2026.
  • Quadrant Capital Group bought 7,153 Edwards Lifesciences shares in Q1 2026, an estimated $590K.
  • Edwards Lifesciences made up 0.05% of Quadrant Capital Group's portfolio in Q1 2026, its #313 holding.
  • Quadrant Capital Group first reported a position in Edwards Lifesciences in Q2 2015 and has held it in 44 quarters since.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.